Terminal Complement Inhibitor Eculizumab in Adult Patients with Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Atypical Hemolytic Uremic Syndrome

abstract

  • Results highlight the benefits of eculizumab in adult patients with aHUS: improvement in hematologic, renal, and quality-of-life parameters; dialysis discontinuation; and transplant protection.

publication date

  • July 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1053/j.ajkd.2015.12.034

PubMed ID

  • 27012908

Additional Document Info

start page

  • 84

end page

  • 93

volume

  • 68

number

  • 1